Charles Schwab Investment Management Inc. increased its position in Exact Sciences Co. (NASDAQ:EXAS - Free Report) by 3.0% in the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 1,330,939 shares of the medical research company's stock after purchasing an additional 38,849 shares during the period. Charles Schwab Investment Management Inc. owned about 0.72% of Exact Sciences worth $74,785,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Grandfield & Dodd LLC boosted its position in shares of Exact Sciences by 4.8% in the fourth quarter. Grandfield & Dodd LLC now owns 108,961 shares of the medical research company's stock worth $6,123,000 after buying an additional 4,962 shares during the period. SBI Securities Co. Ltd. purchased a new stake in shares of Exact Sciences in the fourth quarter worth approximately $66,000. Jones Financial Companies Lllp boosted its stake in shares of Exact Sciences by 32.2% during the 4th quarter. Jones Financial Companies Lllp now owns 9,508 shares of the medical research company's stock valued at $534,000 after buying an additional 2,315 shares during the period. Fisher Asset Management LLC grew its holdings in shares of Exact Sciences by 43.7% during the 4th quarter. Fisher Asset Management LLC now owns 176,637 shares of the medical research company's stock valued at $9,925,000 after acquiring an additional 53,735 shares in the last quarter. Finally, Generali Investments Towarzystwo Funduszy Inwestycyjnych increased its stake in shares of Exact Sciences by 33.3% in the fourth quarter. Generali Investments Towarzystwo Funduszy Inwestycyjnych now owns 24,000 shares of the medical research company's stock worth $1,349,000 after acquiring an additional 6,000 shares during the last quarter. 88.82% of the stock is currently owned by hedge funds and other institutional investors.
Exact Sciences Stock Performance
Exact Sciences stock traded up $1.96 during mid-day trading on Friday, reaching $45.00. The company had a trading volume of 1,704,011 shares, compared to its average volume of 2,337,978. The company has a 50 day moving average of $52.26 and a 200-day moving average of $59.06. Exact Sciences Co. has a 52 week low of $40.62 and a 52 week high of $79.62. The company has a quick ratio of 1.93, a current ratio of 2.15 and a debt-to-equity ratio of 0.97. The firm has a market cap of $8.36 billion, a price-to-earnings ratio of -8.08 and a beta of 1.25.
Exact Sciences (NASDAQ:EXAS - Get Free Report) last released its earnings results on Wednesday, February 19th. The medical research company reported ($0.06) earnings per share for the quarter, topping analysts' consensus estimates of ($0.29) by $0.23. The business had revenue of $713.42 million for the quarter, compared to the consensus estimate of $701.45 million. Exact Sciences had a negative return on equity of 5.29% and a negative net margin of 37.29%. On average, sell-side analysts expect that Exact Sciences Co. will post -0.58 EPS for the current fiscal year.
Wall Street Analyst Weigh In
A number of analysts recently issued reports on the company. Scotiabank lifted their price objective on Exact Sciences from $70.00 to $73.00 and gave the company a "sector outperform" rating in a research report on Monday, February 24th. TD Cowen lifted their target price on shares of Exact Sciences from $82.00 to $86.00 and gave the company a "buy" rating in a research note on Tuesday, November 26th. Barclays decreased their target price on shares of Exact Sciences from $70.00 to $65.00 and set an "overweight" rating for the company in a research report on Thursday, February 20th. Bank of America cut their price target on shares of Exact Sciences from $72.00 to $65.00 and set a "buy" rating on the stock in a report on Thursday, February 20th. Finally, William Blair reiterated an "outperform" rating on shares of Exact Sciences in a report on Thursday, February 20th. Two equities research analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $70.83.
Read Our Latest Stock Analysis on Exact Sciences
Exact Sciences Company Profile
(
Free Report)
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.
Featured Articles
Before you consider Exact Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Exact Sciences wasn't on the list.
While Exact Sciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
